Companhia Siderúrgica Nacional (SID)
NYSE: SID · Real-Time Price · USD
0.9100
-0.0160 (-1.73%)
At close: Jul 8, 2026, 4:00 PM EDT
0.9222
+0.0122 (1.34%)
After-hours: Jul 8, 2026, 7:00 PM EDT
Companhia Siderúrgica Nacional Employees
Companhia Siderúrgica Nacional had 29,000 employees as of December 31, 2025. The number of employees increased by 4,076 or 16.35% compared to the previous year.
Employees
29,000
Change
4,076
Growth
16.35%
Revenue / Employee
$294,108
Profits / Employee
-$13,212
Market Cap
1.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 29,000 | - | - |
| Dec 31, 2022 | 24,924 | 237 | 0.96% |
| Dec 31, 2021 | 24,687 | 1,491 | 6.43% |
| Jun 30, 2021 | 23,000 | - | - |
| Mar 31, 2021 | 23,000 | -1,869 | -7.52% |
| Dec 31, 2020 | 23,196 | -1,673 | -6.73% |
| Dec 31, 2019 | 24,869 | 1,170 | 4.94% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ternium | 33,253 |
| Gerdau | 25,817 |
| Cleveland-Cliffs | 25,000 |
| Grupo Simec | 4,872 |
| Worthington Steel | 4,800 |
| Algoma Steel Group | 2,400 |
| Metallus | 1,865 |
| NWPX Infrastructure | 1,318 |
SID News
- 7 weeks ago - National Steel Q1 Earnings Call Highlights - MarketBeat
- 7 weeks ago - National Steel Q1 Earnings Call Highlights - Nasdaq
- 7 weeks ago - Companhia Siderúrgica Nacional Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Companhia Siderúrgica Nacional Earnings release: Q1 2026 - Filings
- 7 weeks ago - Companhia Siderúrgica Nacional Slides: Q1 2026 - Filings
- 7 weeks ago - Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire
- 2 months ago - TRexBio to Present Late-Breaking Data at the Society for Investigative Dermatology (SID) Annual Meeting Supporting TNFR2 Agonism as a Therapeutic Strategy for Atopic Dermatitis - Business Wire
- 2 months ago - Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting - GlobeNewsWire